514 related articles for article (PubMed ID: 28259011)
1. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
Duffy MJ; Harbeck N; Nap M; Molina R; Nicolini A; Senkus E; Cardoso F
Eur J Cancer; 2017 Apr; 75():284-298. PubMed ID: 28259011
[TBL] [Abstract][Full Text] [Related]
2. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
Duffy MJ; Walsh S; McDermott EW; Crown J
Adv Clin Chem; 2015; 71():1-23. PubMed ID: 26411409
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive biomarkers in breast cancer: Past, present and future.
Nicolini A; Ferrari P; Duffy MJ
Semin Cancer Biol; 2018 Oct; 52(Pt 1):56-73. PubMed ID: 28882552
[TBL] [Abstract][Full Text] [Related]
5. Validated biomarkers: The key to precision treatment in patients with breast cancer.
Duffy MJ; O'Donovan N; McDermott E; Crown J
Breast; 2016 Oct; 29():192-201. PubMed ID: 27521224
[TBL] [Abstract][Full Text] [Related]
6. Biomarker assessment and molecular testing for prognostication in breast cancer.
Kos Z; Dabbs DJ
Histopathology; 2016 Jan; 68(1):70-85. PubMed ID: 26768030
[TBL] [Abstract][Full Text] [Related]
7. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
8. Markers of progression and invasion in short term follow up of untreated breast cancer patients.
Rabi ZA; Todorović-Raković N; Vujasinović T; Milovanović J; Nikolić-Vukosavljević D
Cancer Biomark; 2015; 15(6):745-54. PubMed ID: 26406416
[TBL] [Abstract][Full Text] [Related]
9. Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas.
Sereff SB; Daniels MW; Wittliff JL
J Clin Lab Anal; 2019 Nov; 33(9):e22982. PubMed ID: 31359505
[TBL] [Abstract][Full Text] [Related]
10. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.
Dowsett M; Dunbier AK
Clin Cancer Res; 2008 Dec; 14(24):8019-26. PubMed ID: 19088018
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for the clinical management of breast cancer: international perspective.
Patani N; Martin LA; Dowsett M
Int J Cancer; 2013 Jul; 133(1):1-13. PubMed ID: 23280579
[TBL] [Abstract][Full Text] [Related]
12. [uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].
Bellocq JP; Luporsi E; Barrière J; Bonastre J; Chetritt J; Le Corroller AG; de Crémoux P; Fina F; Gauchez AS; Kassab-Chahmi D; Lamy PJ; Martin PM; Mazouni C; Peyrat JP; Romieu G; Verdoni L; Mazeau-Woynar V
Ann Pathol; 2014 Oct; 34(5):349-51. PubMed ID: 25439987
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
[TBL] [Abstract][Full Text] [Related]
14. ASO Author Reflections: Oncotype DX RS Complementing the Prognostic Stage in the Updated AJCC 8th Edition for T
Wang M; Wu K; Chen H
Ann Surg Oncol; 2019 May; 26(5):1236-1237. PubMed ID: 30706224
[No Abstract] [Full Text] [Related]
15. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
Tong D; Schneeberger C; Czerwenka K; Schmutzler RK; Speiser P; Kucera E; Concin N; Kubista E; Leodolter S; Zeillinger R
Clin Cancer Res; 1999 Jun; 5(6):1497-502. PubMed ID: 10389938
[TBL] [Abstract][Full Text] [Related]
16. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
[TBL] [Abstract][Full Text] [Related]
17. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T
BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461
[TBL] [Abstract][Full Text] [Related]
18. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.
Eppenberger U; Kueng W; Schlaeppi JM; Roesel JL; Benz C; Mueller H; Matter A; Zuber M; Luescher K; Litschgi M; Schmitt M; Foekens JA; Eppenberger-Castori S
J Clin Oncol; 1998 Sep; 16(9):3129-36. PubMed ID: 9738585
[TBL] [Abstract][Full Text] [Related]
19. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program.
Francis GD; Dimech M; Giles L; Hopkins A
J Clin Pathol; 2007 Nov; 60(11):1277-83. PubMed ID: 17259294
[TBL] [Abstract][Full Text] [Related]
20. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?
Falck AK; Fernö M; Bendahl PO; Rydén L
World J Surg; 2010 Jul; 34(7):1434-41. PubMed ID: 20213203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
